临床监察员(CRA)
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2020-11-05
- 工作地点:武汉
- 招聘人数:1人
- 工作经验:2年经验
- 学历要求:本科
- 语言要求:英语熟练
- 职位月薪:5-25万/年
- 职位类别:临床数据分析员
职位描述
岗位职责:
1、遵照GCP、研究方案、项目计划及公司要求,启动、监查和结束临床试验;
2、按照项目计划,与试验中心沟通、协调,负责试验启动、研究者培训、进度跟踪;
3、按照监查计划定期对研究中心进行实地监查,确保研究者按照方案、GCP、SOP等相关要求进行试验;
4、协助研究者及时完成数据疑问,及时、完整地收集研究相关资料;
5、定期、如实向公司提交工作报告,及时处理各种突发事件;
6、维护好各临床中心机构、伦理及科室关系。
任职要求:
a、临床医学或药学相关专业本科及以上学历。
b、2年及以上药物临床试验监察经验,有单抗类药物或肿瘤、风湿免疫、眼科适应症项目经验的优先。
c、具有良好的抗压能力和执行力;良好的应变、沟通和协调能力。
d、性格外向,为人诚信、细致、严谨,有较强的责任感;适应频繁出差。
职能类别:临床数据分析员
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)